Aspen Pharmacare, pursuing J&J vaccine license, aims to shore up local capacity and quash shot inequality in Africa

History is repeating for Aspen Pharmacare. Nearly 20 years ago, as Africa grappled with an HIV epidemic, Aspen pioneered the first generic antiretroviral on the continent. Now, it has a chance to do something similar with Johnson & Johnson's COVID-19 vaccine.